Acknowledgement to Referees.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 12, p. 1279, doi. 10.1007/s40273-020-00977-5
- Publication type:
- Article
Works matching IS 11707690 AND DT 2020 AND VI 38 AND IP 12
Results: 12
1
2
Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".
- Published in:
- 2020
- By:
- Publication type:
- Letter
3
Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".
- Published in:
- 2020
- By:
- Publication type:
- Letter
4
Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974–2018.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
5
Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 12, p. 1359, doi. 10.1007/s40273-020-00962-y
- By:
- Publication type:
- Article
6
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 12, p. 1345, doi. 10.1007/s40273-020-00961-z
- By:
- Publication type:
- Article
7
Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 12, p. 1333, doi. 10.1007/s40273-020-00960-0
- By:
- Publication type:
- Article
8
The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D?
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 12, p. 1283, doi. 10.1007/s40273-020-00957-9
- By:
- Publication type:
- Article
9
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 12, p. 1297, doi. 10.1007/s40273-020-00956-w
- By:
- Publication type:
- Article
10
Sustainability of Publicly Funded Health Care Systems: What Does Behavioural Economics Offer?
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 12, p. 1289, doi. 10.1007/s40273-020-00955-x
- By:
- Publication type:
- Article
11
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 12, p. 1319, doi. 10.1007/s40273-020-00954-y
- By:
- Publication type:
- Article
12
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 12, p. 1309, doi. 10.1007/s40273-020-00953-z
- By:
- Publication type:
- Article